ANEUVO, a Los Angeles-based medical technology company developing non-invasive neuromodulation therapies, announced the closing of a $22 million series C funding round led by Catcher Technology Co., Ltd., with participation from additional new investors.
The financing will support the company’s next phase of growth as it expands manufacturing capabilities, strengthens quality systems, and advances regulatory initiatives for its ExaStim Stimulation System.
Company leadership said the capital will enable ANEUVO to expand operations in approved markets while continuing to build the infrastructure necessary for long-term commercialization and regulatory readiness. The funding will also support sales expansion and additional clinical and real-world evidence generation intended to drive market adoption of the technology.
ANEUVO’s ExaStim Stimulation System delivers personalized spinal cord stimulation designed to support functional neurorehabilitation for patients living with paralysis due to spinal cord injury. The portable neurostimulation device sends electrical pulses through a 16-channel multi-electrode array that stimulates nerves along the spinal cord and dorsal roots.
The system is controlled through proprietary programming software on a mobile digital device. ExaStim has received a CE mark for use in the European Union and is currently classified as an investigational device in the United States, where it is limited to investigational use under federal law.
Through its broader bioelectronic medicine platform, ANEUVO is focused on developing therapies designed to restore functional independence and improve quality of life for people living with disabling diseases and conditions.
KEY QUOTES:
“This financing strengthens the operational and regulatory foundation required to responsibly scale ExaStim. We are focused on disciplined execution — building manufacturing readiness, advancing regulatory initiatives, and expanding access in approved markets in a measured and sustainable manner.”
Yi-Kai Lo, CEO And Co-Founder, ANEUVO
“We are pleased to support ANEUVO at this important stage of its development. The company has demonstrated meaningful progress in advancing its non-invasive neuromodulation platform and has built a strong technical and operational foundation. We believe its disciplined approach to regulatory and commercial execution positions it well to scale operations and expand commercial activities in approved markets. We look forward to supporting the leadership team as they advance their regulatory and manufacturing roadmap.”
Catcher Technology Co., Ltd.
